文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

吸入性前列环素治疗急性呼吸窘迫综合征:系统评价与Meta分析

Inhaled Prostacyclins for Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis.
PubMed 文献 · Crit Care Explor · 2023-06-08
一句话结论在ARDS患者中,吸入性前列环素可提高PaO2/FiO2比值并降低平均肺动脉压,但证据质量极低且异质性高。

该系统评价与Meta分析检索了Ovid Medline、Embase、CINAHL、Cochrane、Scopus和Web of Science,纳入23项研究共1658例ARDS患者,评估吸入性前列环素对氧合及肺动脉压的影响。结果显示,吸入性前列环素较基线提高PaO2/FiO2比值(MD 40.35,95%CI 26.14-54.56,p<0.00001,I2=95%,证据质量极低),8项研究显示提高PaO2(MD 12.68 mmHg,95%CI 2.89-22.48,p=0.01,I2=96%,证据质量极低),3项研究显示降低mPAP(MD -3.67 mmHg,95%CI -5.04至-2.31,p<0.00001,I2=68%,证据质量极低)。作者认为总体数据有限,纳入研究存在高偏倚风险和高异质性,未来研究应评估其在ARDS亚表型(包括心肺ARDS)中的作用。

要点

  • 在ARDS患者中,吸入性前列环素较基线提高PaO2/FiO2比值(MD 40.35,95%CI 26.14-54.56,p<0.00001,I2=95%,证据质量极低)。
  • 8项研究显示吸入性前列环素较基线提高PaO2(MD 12.68 mmHg,95%CI 2.89-22.48,p=0.01,I2=96%,证据质量极低)。
  • 3项研究显示吸入性前列环素较基线降低mPAP(MD -3.67 mmHg,95%CI -5.04至-2.31,p<0.00001,I2=68%,证据质量极低)。
  • 总体数据有限,纳入研究存在高偏倚风险和高异质性。
  • 作者建议未来研究应评估吸入性前列环素在ARDS亚表型(包括心肺ARDS)中的作用。

适用人群与场景

  • 纳入评估吸入性前列环素用于ARDS患者的摘要和试验。

研究设计与关键结果

  • 系统评价与Meta分析纳入23项研究共1658例患者,源自检索策略识别的6339篇摘要。
  • 吸入性前列环素较基线提高PaO2/FiO2比值(MD 40.35,95%CI 26.14-54.56,p<0.00001,I2=95%,证据质量极低)。
  • 8项评估PaO2变化的研究中,吸入性前列环素较基线提高PaO2(MD 12.68 mmHg,95%CI 2.89-22.48,p=0.01,I2=96%,证据质量极低)。
  • 仅3项研究评估mPAP变化,吸入性前列环素较基线降低mPAP(MD -3.67 mmHg,95%CI -5.04至-2.31,p<0.00001,I2=68%,证据质量极低)。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,采用GRADE评估证据质量和Cochrane偏倚风险工具评估偏倚风险。
  • 局限:总体数据有限,纳入研究存在高偏倚风险和高异质性;证据质量极低。
  • 作者指出未来研究应评估吸入性前列环素在ARDS亚表型(包括心肺ARDS)中的作用。

对床旁实践的改变

  • 在ARDS患者中,吸入性前列环素可能改善氧合(提高PaO2/FiO2比值和PaO2)并降低平均肺动脉压,但证据质量极低且异质性高,作者未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Studies evaluating inhaled prostacyclins for the management of acute respiratory distress syndrome (ARDS) have produced inconsistent results regarding their effect on oxygenation. The purpose of this systematic review and meta-analysis was to evaluate the change in the Pao2/Fio2 ratio after administration of an inhaled prostacyclin in patients with ARDS.

DATA SOURCES: We searched Ovid Medline, Embase, Cumulative Index to Nursing and Allied Health Literature, Cochrane, Scopus, and Web of Science.

STUDY SELECTION: We included abstracts and trials evaluating administration of inhaled prostacyclins in patients with ARDS.

DATA EXTRACTION: Change in the Pao2/Fio2 ratio, Pao2, and mean pulmonary artery pressure (mPAP) were extracted from included studies. Evidence certainty and risk of bias were evaluated using Grading of Recommendations Assessment, Development, and Evaluation and the Cochrane Risk of Bias tool.

DATA SYNTHESIS: We included 23 studies (1,658 patients) from 6,339 abstracts identified by our search strategy. The use of inhaled prostacyclins improved oxygenation by increasing the Pao2/Fio2 ratio from baseline (mean difference [MD], 40.35; 95% CI, 26.14-54.56; p < 0.00001; I2 = 95%; very low quality evidence). Of the eight studies to evaluate change in Pao2, inhaled prostacyclins also increased Pao2 from baseline (MD, 12.68; 95% CI, 2.89-22.48 mm Hg; p = 0.01; I2 = 96%; very low quality evidence). Only three studies evaluated change in mPAP, but inhaled prostacyclins were found to improve mPAP from baseline (MD, -3.67; 95% CI, -5.04 to -2.31 mm Hg; p < 0.00001; I2 = 68%; very low quality evidence).

CONCLUSIONS: In patients with ARDS, use of inhaled prostacyclins improves oxygenation and reduces pulmonary artery pressures. Overall data are limited and there was high risk of bias and heterogeneity among included studies. Future studies evaluating inhaled prostacyclins for ARDS should evaluate their role in ARDS subphenotypes, including cardiopulmonary ARDS.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Torbic H, Saini A, Harnegie MP, et al. Inhaled Prostacyclins for Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis. Crit Care Explor. 2023. PMID: 37303944. doi:10.1097/CCE.0000000000000931

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。